NCT04686383 - Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

June 7, 2022

Study Completion Date

June 30, 2022

Conditions

Resistant or Refractory Solid Tumors

Interventions

DRUG

CAL056 mesylate

Dosage form: 20 mg CAL056 mesylate/tablet

Trial Locations (3)

NEXT Oncology, 2829 Babcock Road Suite 300, San Antonio

USC Norris Comprehensive Cancer Center, Los Angeles

Tzu Chi General Hospital, Taipei Branch, New Taipei City